- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Fall 2014
| Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Combivir | ViiV Healthcare | Lamivudine and Zidovudine Tablets USP | Mylan | treatment of HIV-1 infection in combination with other antiretroviral (ARV) agents | 10/3/2014 |
| Precedex | Hospira | Dexmedetomidine Hydrochloride | Sandoz | sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting and the sedation of non-intubated patients prior to and/or during surgical and other procedures | 10/6/2014 |
| Rapamune | Wyeth | Sirolimus Tablets | Dr. Reddy's Labs. | prophylaxis of organ rejection in patients aged ≥ 13 years receiving renal transplants |
10/27/2014 |
| Viramune XR | Boehringer Ingelheim | Nevirapine Extended-Release Tablets | Mylan | for combination antiretroviral (ARV) treatment of HIV-1 infection in adults and in children 6 to < 18 years of age | 10/30/2014 |
| Prilosec | AstraZeneca | Omeprazole Delayed-Release Capsules | Glenmark Generics | short-term treatment of active duodenal ulcer in adults | 11/5/2014 |
| Zemplar | AbbVie | Paricalcitol Injection | Hospira | prevention and treatment of secondary hyperparathyroidism associated with Stage 5 Chronic Kidney Disease (CKD) | 11/5/2014 |
| Loestrin 24 Fe | Warner Chilcott | Norethindrone Acetate / Ethinyl Estradiol Tablets and Ferrous Fumarate | Mylan | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 11/5/2014 |
| Antara | Lupin Atlantis | Fenofibrate Capsules | Ranbaxy Labs. | for primary hypercholesterolemia and mixed dyslipidemia | 11/5/2014 |
| Cytoxan | Baxter Healthcare | Cyclophosphamide Injection | Sandoz | chemotherapy agent to treat certain types of cancer in adults and pediatric patients | 11/10/2014 |
| Activella | Novo Nordisk | Estradiol / Norethindrone Acetate Tablets | Amneal Pharms. | treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis | 11/20/2014 |
| Allegra-D | Aventisub II | Fexofenadine Hydrochloride / Pseudoephedrine Hydrochloride Extended-Release Tablets | Dr. Reddy's Labs. | allergy and nasal congestion | 11/20/2014 |
| Valcyte | Hoffman-La Roche | Valganciclovir Tablets | Endo Pharms. | treatment of cytomegalovirus (CMV) disease | 11/20/2014 |
| Taxotere | Aventis Pharma | Docetaxel Injection USP | Dr. Reddy's Labs. | microtubule inhibitor indicated for the treatment of breast cancer, non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck cancer | 11/24/2014 |
| Protopic Ointment | Astellas U.S. | Tacrolimus | Perrigo | treat moderate to severe eczema | 11/24/2014 |
| Intuniv | Shire | Guanfacine Hydrochloride | Actavis | treat Attention Deficit Hyperactivity Disorder in patients ages 6 to 17 | 12/1/2014 |
| Exforge HCT | Novartis Pharms. | Amlodipine / Valsartan / Hydrochlorothiazide Tablets | Teva | treatment of hypertension to lower blood pressure | 12/1/2014 |
| Pennsaid | Mallinckrodt | Diclofenac Sodium Topical Solution 1.5% w/w | Perrigo | treatment of signs and symptoms of osteoarthritis of the knee(s) | 12/2/2014 |
| Celebrex | Pfizer | Celecoxib Capsules | Actavis | relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults | 12/10/2014 |
| Celebrex | G.D. Searle | Celecoxib Capsules | Lupin Pharms. | relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults | 12/11/2014 |
| Orapred ODT | Shionogi | Prednisolone Sodium Phosphate Orally-Disintegrating Tablets | Mylan | an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions | 12/11/2014 |
| Robaxin | Hikma Maple | Methocarbamol Injection | Mylan | adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions | 12/11/2014 |
| Valcyte | Hoffman-La Roche | Valganciclovir Tablets | Dr. Reddy's Labs. | treatment of cytomegalovirus (CMV) disease | 12/16/2014 |
| Vivelle-Dot | Novartis Pharms. | Estradiol Transdermal System USP | Mylan | treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis | 12/22/2014 |
| Vivelle-Dot | Novartis Pharms. | Estradiol Transdermal System | Sandoz | treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis | 12/22/2014 |
| Epivir | ViiV Healthcare | Lamivudine Tablets | Lupin Pharms. | treatment of human immunodeficiency virus (HIV-1) infection | 12/26/2014 |
| Coly-Mycin M | Par Sterile Products | Colistimethate Sodium | Sagent Pharms. | treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli | 12/30/2014 |
GENERICally Speaking Winter 2014
Related Professionals
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.